Wavozen

313 SAN. triangle breakout plus wave3 (3 to 5 days)

Long
Wavozen Updated   
NSE:AUROPHARMA   AUROBINDO PHARMA

Disclaimer: Set-up shown here is only for educational purpose only; This is not a sell or buy recommendation. We are not responsible for any gain or loss; Consult your financial advisor before your execution of any recommended trade.
There are heavy chance that most of the presented scripts does not meet set (described) entry conditions, as most of the posted analysis are based on Static ANalysis (SAN). Many times Market does not provides good and ideal entry points. Hence needs personalized intraday techniques and strategies (PITS) for your entries and exists (Profit taking point 1 (PT1 or PT2) or Stop loss points (SL)). Always run with SL.
Set-up presented here is for observational purpose only and most of the set-up designed by WavoZen is based on SAN for intraday purpose only to get the basic structure for intra-day short term or ultra-short term purpose only. Most of the set-up is valid for a day or otherwise mentioned. Hence requires your fine tuned personalized intraday techniques and strategies (PITS) based on Real-time Analysis (RT)/ Dynamic ANalysis (DAN) to get benefit from these structures or to have minimum loss, if wrong through your PIT Strategies (your trade plan). Overnight events, Gap-up opening, gap-down opening, news, major economic data release etc may impact the deviation from the assumed scenarios. If entry conditions and criteria are not meet, then we should not take any chance to enter on assumed scenarios. (ENT= Entry not triggered). If there is a deviation in assumed scenario in time, speed and angle and these deviations will not encourages for entry as referred as entry not valid (ENV). Daily post appears on stocktwits.WavoZen.
Order cancelled:
Entry only after showing the strength or demonstrating weakness in pullback and these are not happened in Auropharma; Hence Entry not triggered (ENT).
This is the perfect example demonstrating the PITS and importance of SL.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.